Addressing the huge unmet treatment need for patients with EGFR-mutated stage III unresectable NSCLC, the LAURA trial represents the first international Phase 3 clinical trial to directly compare the safety and efficacy of osimertinib with placebo in these patients after chemoradiotherapy, potentially establishing osimertinib as a new standard of care (20). Here, EGFR is linked to non-small cell lung carcinoma.